title: The wound healing properties of Channa striatus-cetrimide cream-wound contraction and glycosaminoglycan measurement.
abstract: Haruan has been proved to influence the different phases of wound healing process. The current research focuses on the effects of haruan on the different constituents of extracellular matrix of healing wounds in normal and diabetic rats. Anaesthetized normal and streptozotocin induced diabetic rats were provided with excision wounds at the back and then animals were divided into four groups as: group 1, wounds treated with cetrimide+haruan cream; group 2, wounds treated with haruan cream; group 3, wounds treated with cetrimide (commercial) cream; and group 4, wounds untreated and served as control. Animals were sacrificed after 3, 6, 9 and 12 days. These wounds were used to determine the hexosamine, protein, uronic acid and glycosaminoglycan contents and the wound contraction. The results suggested a marked increase (P<0.05) in the uronic acid, hexosamine and dermatan sulfate contents on day 3 of group 1 when compared with groups 2-4. Wound contraction of group 1 was also markedly enhanced of group 1 (P<0.01) when compared with groups 2- 4. On the basis of these results, we conclude that haruan enhances the synthesis of different glycosaminoglycans in healing wounds, which are the first component of extracellular matrix to be synthesized during the wound healing process. The enhanced levels of glycosaminoglycans may help in the formation of a resistant scar and enhanced wound contraction represents the positive influence of haruan on the fibroplastic phase of wound healing.
authors.affiliation: Department of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Penang, Malaysia. saringat@usm.my
authors.forename: S H
authors.initials: SH
authors.lastname: Baie
authors.forename: K A
authors.initials: KA
authors.lastname: Sheikh
mesh_terms: D000818:Animals; D000891:Anti-Infective Agents, Local / Q000494:pharmacology / Q000627:therapeutic use*; D000077286:Cetrimonium; D002593:Cetrimonium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005109:Extracellular Matrix / Q000378:metabolism*; D006025:Glycosaminoglycans / Q000378:metabolism*; D008297:Male; D009824:Ointments; D010936:Plant Extracts / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014574:Uronic Acids / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000378:metabolism*
chemical_list: D000891:Anti-Infective Agents, Local; D002593:Cetrimonium Compounds; D006025:Glycosaminoglycans; D009824:Ointments; D010936:Plant Extracts; D014574:Uronic Acids; D000077286:Cetrimonium